Aldosterone: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett |
imported>Robert Badgett |
||
| Line 6: | Line 6: | ||
[[Primary aldosteronism]] underlies about 10% of cases of resistant [[hypertension]].<ref name="pmid18539224">{{cite journal |author=Douma S, Petidis K, Doumas M, ''et al'' |title=Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study |journal=Lancet |volume=371 |issue=9628 |pages=1921–6 |year=2008 |month=June |pmid=18539224 |doi=10.1016/S0140-6736(08)60834-X |url=http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(08)60834-X |issn=}}</ref> | [[Primary aldosteronism]] underlies about 10% of cases of resistant [[hypertension]].<ref name="pmid18539224">{{cite journal |author=Douma S, Petidis K, Doumas M, ''et al'' |title=Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study |journal=Lancet |volume=371 |issue=9628 |pages=1921–6 |year=2008 |month=June |pmid=18539224 |doi=10.1016/S0140-6736(08)60834-X |url=http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(08)60834-X |issn=}}</ref> | ||
[[Clinical practice guideline]]s are available for managing primary aldosteronism.<ref name="pmid18552288">{{cite journal| author=Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M et al.| title=Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. | journal=J Clin Endocrinol Metab | year= 2008 | volume= 93 | issue= 9 | pages= 3266-81 | pmid=18552288 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18552288 | doi=10.1210/jc.2008-0104 }} [http://www.endo-society.org/guidelines/final/upload/Final-Standalone-PA-Guideline.pdf Free fulltext]</ref> | [[Clinical practice guideline]]s are available for managing primary aldosteronism.<ref name="pmid18552288">{{cite journal| author=Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M et al.| title=Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. | journal=J Clin Endocrinol Metab | year= 2008 | volume= 93 | issue= 9 | pages= 3266-81 | pmid=18552288 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18552288 | doi=10.1210/jc.2008-0104 }} [http://www.endo-society.org/guidelines/final/upload/Final-Standalone-PA-Guideline.pdf Free fulltext]</ref> A aldosterone renin ratio (ARR) over 20 with an elevated aldosterone level suggests primary hyperaldosteronism.<ref name="pmid18552288"/> | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 14:36, 20 October 2010
Aldosterone, also called (11ß)-11,21-Dihydroxy-3,20-dioxo-pregn-4-en-18-al, is a steroid hormone. It is the major mineralcorticoid and it therefore controls electrolyte levels, blood pressure and hydration. Aldosterone is synthesized from corticosterone by oxidation of the C-18 methyl group to form an aldehyde.
Primary aldosteronism
Primary aldosteronism underlies about 10% of cases of resistant hypertension.[1]
Clinical practice guidelines are available for managing primary aldosteronism.[2] A aldosterone renin ratio (ARR) over 20 with an elevated aldosterone level suggests primary hyperaldosteronism.[2]
References
- ↑ Douma S, Petidis K, Doumas M, et al (June 2008). "Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study". Lancet 371 (9628): 1921–6. DOI:10.1016/S0140-6736(08)60834-X. PMID 18539224. Research Blogging.
- ↑ 2.0 2.1 Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M et al. (2008). "Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline.". J Clin Endocrinol Metab 93 (9): 3266-81. DOI:10.1210/jc.2008-0104. PMID 18552288. Research Blogging. Free fulltext